Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers

Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic ta...

Full description

Saved in:
Bibliographic Details
Published inAdvanced biomedical research Vol. 8; no. 1; p. 63
Main Authors Sanaei, Masumeh, Kavoosi, Fraidoon
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer India Pvt. Ltd 01.01.2019
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer - Medknow
Wolters Kluwer Medknow Publications
Subjects
Online AccessGet full text
ISSN2277-9175
2277-9175
DOI10.4103/abr.abr_142_19

Cover

Abstract Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic target because of its role in regulating gene expression. HDAC inhibitors (HDACIs) are a family of synthetic and natural compounds that differ in their target specificities and activities. They affect markedly cancer cells, inducing cell differentiation, cell cycle arrest and cell death, reduction of angiogenesis, and modulation of the immune system. Here, we summarize the mechanisms of HDACs and the HDACIs in several cancers. An online search of different sources such as PubMed, ISI, and Scopus was performed to find available data on mechanisms and pathways of HDACs and HDACIs in different cancers. The result indicated that HDACs induce cancer through multiple mechanisms in various tissues. This effect can be inhibited by HDACIs which affect cancer cell by different pathways such as cell differentiation, cell cycle arrest, and cell death. In conclusion, these findings indicate that the HDACs play a major role in carcinogenesis through various pathways, and HDACIs can inhibit HDAC activity by multiple mechanisms resulting in cell cycle arrest, cell growth inhibition, and apoptosis induction.
AbstractList Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic target because of its role in regulating gene expression. HDAC inhibitors (HDACIs) are a family of synthetic and natural compounds that differ in their target specificities and activities. They affect markedly cancer cells, inducing cell differentiation, cell cycle arrest and cell death, reduction of angiogenesis, and modulation of the immune system. Here, we summarize the mechanisms of HDACs and the HDACIs in several cancers. An online search of different sources such as PubMed, ISI, and Scopus was performed to find available data on mechanisms and pathways of HDACs and HDACIs in different cancers. The result indicated that HDACs induce cancer through multiple mechanisms in various tissues. This effect can be inhibited by HDACIs which affect cancer cell by different pathways such as cell differentiation, cell cycle arrest, and cell death. In conclusion, these findings indicate that the HDACs play a major role in carcinogenesis through various pathways, and HDACIs can inhibit HDAC activity by multiple mechanisms resulting in cell cycle arrest, cell growth inhibition, and apoptosis induction.
Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic target because of its role in regulating gene expression. HDAC inhibitors (HDACIs) are a family of synthetic and natural compounds that differ in their target specificities and activities. They affect markedly cancer cells, inducing cell differentiation, cell cycle arrest and cell death, reduction of angiogenesis, and modulation of the immune system. Here, we summarize the mechanisms of HDACs and the HDACIs in several cancers. An online search of different sources such as PubMed, ISI, and Scopus was performed to find available data on mechanisms and pathways of HDACs and HDACIs in different cancers. The result indicated that HDACs induce cancer through multiple mechanisms in various tissues. This effect can be inhibited by HDACIs which affect cancer cell by different pathways such as cell differentiation, cell cycle arrest, and cell death. In conclusion, these findings indicate that the HDACs play a major role in carcinogenesis through various pathways, and HDACIs can inhibit HDAC activity by multiple mechanisms resulting in cell cycle arrest, cell growth inhibition, and apoptosis induction.Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic target because of its role in regulating gene expression. HDAC inhibitors (HDACIs) are a family of synthetic and natural compounds that differ in their target specificities and activities. They affect markedly cancer cells, inducing cell differentiation, cell cycle arrest and cell death, reduction of angiogenesis, and modulation of the immune system. Here, we summarize the mechanisms of HDACs and the HDACIs in several cancers. An online search of different sources such as PubMed, ISI, and Scopus was performed to find available data on mechanisms and pathways of HDACs and HDACIs in different cancers. The result indicated that HDACs induce cancer through multiple mechanisms in various tissues. This effect can be inhibited by HDACIs which affect cancer cell by different pathways such as cell differentiation, cell cycle arrest, and cell death. In conclusion, these findings indicate that the HDACs play a major role in carcinogenesis through various pathways, and HDACIs can inhibit HDAC activity by multiple mechanisms resulting in cell cycle arrest, cell growth inhibition, and apoptosis induction.
Audience Academic
Author Sanaei, Masumeh
Kavoosi, Fraidoon
AuthorAffiliation From the Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran
AuthorAffiliation_xml – name: From the Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran
Author_xml – sequence: 1
  givenname: Masumeh
  surname: Sanaei
  fullname: Sanaei, Masumeh
  organization: Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom
– sequence: 2
  givenname: Fraidoon
  surname: Kavoosi
  fullname: Kavoosi, Fraidoon
  organization: Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31737580$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1v0zAAxSM0xMbYlSOyxAUOLXEcf4TDpKrAVmkTEl9Xy3Hs1p1rD9uh7L_Hod26TluiKJH9e8_O83tZHDjvVFG8huW4hiX6INowzg-HdcVh86w4qipKRw2k-ODe92FxEuOyzBdhNcHNi-IQQYooZuVRsTw3MWVX8EkJqdKNFVFFIFwHHpkAM7cwrUk-xI_g0lsleysCuFRyIZyJqwi8BhOZjHfAOPBLBOP7CKbCSRXiq-K5Fjaqk-37uPj55fOP6fno4uvZbDq5GEkKsR0hhDQiZdcyzWpW0gohKlupKVSEaS1JhZHSrGtqCBnTTSsZ0Zg0UKim62CLjovZxrfzYsmvg1mJcMO9MPz_gA9zLkIy0irelQ3schhEtqyuCWmrTteMYIaJFliI7HW68bru25XqpHIpCLtnuj_jzILP_R9OGGoqirLBu61B8L97FRNfmSiVtcKpnA2vEMS4YgQO6NsH6NL3weWoBiqfJsSw2VFzkX_AOO3zunIw5RMCIa1KiHCmxo9Q-e7Uysh8rNrk8T3B-z1BZpL6m-aij5HPvn_bZ9_cD-UujdtW7VaXwccYlL5DYMmH5vKhtbvmZkH9QCBNEkOP8raNfVp2tpGtvU25YVe2X6vA856unF8_oeIE8W23-W230T9g7AtJ
CitedBy_id crossref_primary_10_3390_cancers15061647
crossref_primary_10_3389_fchem_2022_948217
crossref_primary_10_3389_fcell_2023_1224069
crossref_primary_10_1002_hep_32080
crossref_primary_10_1186_s12885_021_08595_w
crossref_primary_10_3390_ijms22115516
crossref_primary_10_1016_j_biopha_2020_110454
crossref_primary_10_1111_cbdd_14366
crossref_primary_10_3390_ijms21217853
crossref_primary_10_3390_jpm12060964
crossref_primary_10_1002_cam4_5694
crossref_primary_10_1016_j_biopha_2022_112762
crossref_primary_10_1186_s13148_022_01370_z
crossref_primary_10_3390_cells9030780
crossref_primary_10_1080_14728222_2023_2240021
crossref_primary_10_1038_s41392_021_00647_8
crossref_primary_10_1016_j_colsurfb_2020_111144
crossref_primary_10_1016_j_ejmech_2021_113824
crossref_primary_10_1016_j_mrrev_2021_108385
crossref_primary_10_1007_s11033_021_06481_z
crossref_primary_10_3389_fcell_2021_719390
crossref_primary_10_1371_journal_pone_0316343
crossref_primary_10_1177_20406207241283277
crossref_primary_10_2174_0929867328666210901144658
crossref_primary_10_3389_fcell_2024_1426508
crossref_primary_10_3389_fbioe_2022_1047851
crossref_primary_10_4103_1735_5362_355214
crossref_primary_10_3892_or_2023_8480
crossref_primary_10_1016_j_bbamcr_2021_118966
crossref_primary_10_1016_j_ejmech_2022_115022
crossref_primary_10_3389_fonc_2022_853034
crossref_primary_10_3390_ph17050620
crossref_primary_10_3389_fonc_2021_741746
crossref_primary_10_4103_1735_5362_350240
crossref_primary_10_1002_cbdv_201900427
crossref_primary_10_1016_j_biopha_2020_110390
crossref_primary_10_3390_cells8121656
crossref_primary_10_1016_j_pharmthera_2024_108749
crossref_primary_10_1515_znc_2024_0140
crossref_primary_10_1016_j_intimp_2023_110428
crossref_primary_10_3389_fimmu_2022_882216
crossref_primary_10_2217_bmm_2020_0170
crossref_primary_10_3389_fonc_2022_1057186
crossref_primary_10_1080_14656566_2024_2331778
crossref_primary_10_3389_fcell_2020_576391
crossref_primary_10_3389_fcell_2020_00546
crossref_primary_10_1016_j_heliyon_2023_e23683
crossref_primary_10_2174_0929867325666181016163110
crossref_primary_10_1016_j_phrs_2021_105802
crossref_primary_10_3390_vaccines12060626
crossref_primary_10_1016_j_abb_2021_108776
crossref_primary_10_1080_17568919_2024_2437975
crossref_primary_10_1515_hsz_2021_0139
crossref_primary_10_1007_s40203_021_00077_y
crossref_primary_10_3390_ijms21155582
crossref_primary_10_3390_cancers13153821
crossref_primary_10_1093_jambio_lxaf014
crossref_primary_10_3389_fgene_2021_767834
crossref_primary_10_1002_bit_28611
crossref_primary_10_3390_cancers13040634
crossref_primary_10_3390_cancers12041016
crossref_primary_10_3390_ijms23158141
crossref_primary_10_1111_cbdd_14239
crossref_primary_10_1186_s13148_022_01228_4
crossref_primary_10_1007_s10637_024_01479_3
crossref_primary_10_35366_97715
crossref_primary_10_3389_fgene_2023_1135404
crossref_primary_10_3389_fphys_2023_1332810
crossref_primary_10_1016_j_cbd_2020_100748
crossref_primary_10_3390_ph17040444
crossref_primary_10_1007_s00203_024_03834_7
crossref_primary_10_1016_j_arr_2021_101312
crossref_primary_10_1152_ajprenal_00405_2020
crossref_primary_10_1007_s12010_022_04107_z
crossref_primary_10_2217_epi_2023_0181
crossref_primary_10_3390_cancers13112761
crossref_primary_10_1016_j_ejmech_2023_115613
Cites_doi 10.1007/s10911-010-9166-0
10.1111/j.1464-410X.2009.08795.x
10.1073/pnas.0307708100
10.1038/sj.bjc.6604199
10.1038/cddis.2016.457
10.1371/journal.pgen.0020040
10.1586/14737140.7.4.583
10.2183/pjab.93.019
10.1016/j.surg.2004.05.018
10.1146/annurev.biochem.76.052705.162114
10.1016/j.cell.2012.06.013
10.1038/sj.onc.1210619
10.4161/cbt.7.4.5480
10.1002/jcb.20532
10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
10.1016/j.canlet.2013.07.022
10.1038/sj.cdd.4401567
10.3892/ijo.2015.3240
10.5483/BMBRep.2009.42.10.655
10.1155/2010/458431
10.1016/S0168-9525(03)00073-8
10.1002/cncr.20709
10.1111/j.1582-4934.2008.00436.x
10.3748/wjg.v13.i33.4458
10.1038/sj.onc.1210602
10.1371/journal.pone.0018087
10.5507/bp.2013.085
10.3390/molecules20033898
10.21037/tlcr.2016.02.02
10.1002/pmic.201000812
10.1593/neo.08474
10.3390/nu10060731
10.1158/1535-7163.MCT-08-0299
10.1200/JCO.2011.41.2395
10.1016/S1535-6108(04)00114-X
10.1097/MD.0000000000007663
10.1158/1078-0432.CCR-04-1092
10.4161/cbt.6.1.3549
10.1186/1472-6890-14-10
10.1038/sj.bjc.6603851
10.1038/nrc1779
10.4161/cbt.6.5.4007
10.1371/journal.pone.0064600
10.1016/j.lungcan.2005.02.006
10.4161/epi.3.6.7273
10.1007/s10549-004-1668-2
10.1093/jb/mvn074
10.1038/sj.onc.1207020
10.1158/0008-5472.CAN-06-0049
10.1002/ijc.25151
10.1186/s12943-018-0855-4
10.1093/emboj/21.11.2672
10.1371/journal.pone.0080657
10.1038/bjc.2016.36
10.1186/1471-2407-8-381
10.1186/1475-2867-11-29
10.1158/1078-0432.CCR-04-0455
10.1016/j.jhep.2012.01.018
10.1002/cbdv.200590118
10.1158/0008-5472.CAN-06-3996
10.1155/2010/923824
10.1016/j.bbamcr.2004.07.001
10.1158/1535-7163.1397.3.11
10.1200/JCO.2007.14.5730
10.1038/nbt1272
10.1038/cr.2011.22
10.1245/s10434-008-9940-z
10.1155/2016/8797206
10.1155/2011/315939
10.1111/j.1349-7006.2009.01387.x
10.2174/092986707782023299
10.1016/j.cell.2007.10.039
10.4161/auto.6.8.13365
10.1155/2015/243298
10.1186/1755-8794-2-67
10.1371/journal.pone.0002020
10.1080/1120009X.2016.1277007
10.1007/s00428-011-1103-0
10.1016/j.bbrc.2006.07.185
10.1158/1078-0432.CCR-07-0014
10.3748/wjg.v19.i6.813
10.1038/nrd2133
10.1371/journal.pone.0136193
10.1186/s12964-018-0231-4
10.1016/S0959-437X(00)00174-X
10.1158/1078-0432.CCR-08-1918
10.1128/MCB.00494-07
10.1016/j.semcancer.2007.04.001
10.1016/j.jhep.2017.03.026
10.1158/1078-0432.CCR-05-0259
ContentType Journal Article
Copyright Copyright: © 2019 Advanced Biomedical Research.
COPYRIGHT 2019 Medknow Publications and Media Pvt. Ltd.
2019. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright: © 2019 Advanced Biomedical Research 2019
Copyright_xml – notice: Copyright: © 2019 Advanced Biomedical Research.
– notice: COPYRIGHT 2019 Medknow Publications and Media Pvt. Ltd.
– notice: 2019. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright: © 2019 Advanced Biomedical Research 2019
DBID AAYXX
CITATION
NPM
ISR
3V.
7X7
7XB
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
L6V
LK8
M0S
M7P
M7S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PTHSS
7X8
5PM
DOA
DOI 10.4103/abr.abr_142_19
DatabaseName CrossRef
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
ProQuest_Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Engineering Collection
Biological Sciences
ProQuest Health & Medical Collection
Biological Science Database
Engineering Database (subscription)
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
Technology Collection
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Engineering Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
Engineering Collection
Engineering Database
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
PubMed
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2277-9175
EndPage 63
ExternalDocumentID oai_doaj_org_article_d091d3176cb84466b2df4865856fa5aa
PMC6839273
A611720135
31737580
10_4103_abr_abr_142_19
10.4103/abr.abr_142_19_63_Histone Deacetyl
Genre Journal Article
Review
GeographicLocations Iran
GeographicLocations_xml – name: Iran
GroupedDBID 5VS
7X7
8FE
8FG
8FH
8FI
8FJ
AAKDD
ABJCF
ABUWG
ACGFS
ACIWK
ACPRK
ADBBV
ADRAZ
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
CCPQU
DIK
FYUFA
GROUPED_DOAJ
GX1
H13
HCIFZ
HMCUK
HYE
IAO
IHR
ISR
ITC
KQ8
L6V
LK8
M48
M7P
M7S
M~E
OK1
OVD
PGMZT
PHGZM
PHGZT
PIMPY
PROAC
PTHSS
RMW
RNS
RPM
TEORI
UKHRP
W3E
AAYXX
CITATION
EMOBN
IPNFZ
RIG
NPM
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c715l-333f360db8f848072337cbcf71e68ffc6253ef8d941188f9bc86f5691ae9dd1b3
IEDL.DBID M48
ISSN 2277-9175
IngestDate Wed Aug 27 01:14:05 EDT 2025
Thu Aug 21 18:20:59 EDT 2025
Fri Sep 05 08:35:49 EDT 2025
Fri Jul 25 11:54:43 EDT 2025
Tue Jun 17 20:59:21 EDT 2025
Tue Jun 10 20:27:55 EDT 2025
Fri Jun 27 04:25:31 EDT 2025
Thu Apr 03 06:59:01 EDT 2025
Thu Apr 24 23:11:56 EDT 2025
Tue Jul 01 03:12:12 EDT 2025
Tue Jun 17 22:50:30 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords histone deacetylase
Cancer
histone deacetylase inhibitors
Language English
License http://creativecommons.org/licenses/by-nc-sa/4.0
Copyright: © 2019 Advanced Biomedical Research.
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c715l-333f360db8f848072337cbcf71e68ffc6253ef8d941188f9bc86f5691ae9dd1b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink https://doaj.org/article/d091d3176cb84466b2df4865856fa5aa
PMID 31737580
PQID 2312771519
PQPubID 2035645
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_d091d3176cb84466b2df4865856fa5aa
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6839273
proquest_miscellaneous_2315528613
proquest_journals_2312771519
gale_infotracmisc_A611720135
gale_infotracacademiconefile_A611720135
gale_incontextgauss_ISR_A611720135
pubmed_primary_31737580
crossref_primary_10_4103_abr_abr_142_19
crossref_citationtrail_10_4103_abr_abr_142_19
wolterskluwer_medknow_10_4103_abr_abr_142_19_63_Histone_Deacetyl
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-1-1-01
PublicationDateYYYYMMDD 2019-01-01
PublicationDate_xml – month: 01
  year: 2019
  text: 2019-1-1-01
  day: 01
PublicationDecade 2010
PublicationPlace India
PublicationPlace_xml – name: India
– name: Mumbai
PublicationTitle Advanced biomedical research
PublicationTitleAlternate Adv Biomed Res
PublicationYear 2019
Publisher Wolters Kluwer India Pvt. Ltd
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Wolters Kluwer - Medknow
Wolters Kluwer Medknow Publications
Publisher_xml – name: Wolters Kluwer India Pvt. Ltd
– name: Medknow Publications and Media Pvt. Ltd
– name: Medknow Publications & Media Pvt. Ltd
– name: Wolters Kluwer - Medknow
– name: Wolters Kluwer Medknow Publications
References Kato (key-10.4103/2277-9175.270133-28) 2007
Baradari (key-10.4103/2277-9175.270133-79) 2007
Bai (key-10.4103/2277-9175.270133-87) 2006
Dawson (key-10.4103/2277-9175.270133-14) 2012
Jakopovic (key-10.4103/2277-9175.270133-92) 2013
Kavoosi (key-10.4103/2277-9175.270133-9) 2018
Sanaei (key-10.4103/2277-9175.270133-11) 2017
Hodawadekar (key-10.4103/2277-9175.270133-21) 2007
Hrabeta (key-10.4103/2277-9175.270133-6) 2014
Chopin (key-10.4103/2277-9175.270133-35) 2004
Asgar (key-10.4103/2277-9175.270133-81) 2016
Weichert (key-10.4103/2277-9175.270133-46) 2008
Cao (key-10.4103/2277-9175.270133-93) 2017
Cha (key-10.4103/2277-9175.270133-30) 2009
LaBonte (key-10.4103/2277-9175.270133-72) 2009
Stypula-Cyrus (key-10.4103/2277-9175.270133-70) 2013
Rizvi (key-10.4103/2277-9175.270133-78) 2017
Shahbazian (key-10.4103/2277-9175.270133-13) 2007
Liu (key-10.4103/2277-9175.270133-76) 2010
Doi (key-10.4103/2277-9175.270133-98) 2004
Yin (key-10.4103/2277-9175.270133-80) 2017
Allis (key-10.4103/2277-9175.270133-4) 2007
Bartling (key-10.4103/2277-9175.270133-95) 2005
Takai (key-10.4103/2277-9175.270133-52) 2004
Zhang (key-10.4103/2277-9175.270133-84) 2015
Wang (key-10.4103/2277-9175.270133-29) 2005
Zhou (key-10.4103/2277-9175.270133-65) 2007
Poyet (key-10.4103/2277-9175.270133-31) 2014
Waltregny (key-10.4103/2277-9175.270133-40) 2004
Quint (key-10.4103/2277-9175.270133-73) 2011
Hull (key-10.4103/2277-9175.270133-7) 2016
Firestein (key-10.4103/2277-9175.270133-17) 2008
Rundall (key-10.4103/2277-9175.270133-99) 2004
Gui (key-10.4103/2277-9175.270133-34) 2004
Weichert (key-10.4103/2277-9175.270133-41) 2008
Takai (key-10.4103/2277-9175.270133-53) 2007
Khochbin (key-10.4103/2277-9175.270133-2) 2001
Cuppens (key-10.4103/2277-9175.270133-54) 2015
key-10.4103/2277-9175.270133-10
key-10.4103/2277-9175.270133-12
key-10.4103/2277-9175.270133-94
Feng (key-10.4103/2277-9175.270133-58) 2013
Ouaïssi (key-10.4103/2277-9175.270133-88) 2008
Abbas (key-10.4103/2277-9175.270133-44) 2008
Ozawa (key-10.4103/2277-9175.270133-33) 2010
Dashwood (key-10.4103/2277-9175.270133-69) 2007
Bannister (key-10.4103/2277-9175.270133-23) 2011
Jones (key-10.4103/2277-9175.270133-36) 2009
Mottamal (key-10.4103/2277-9175.270133-26) 2015
Zhu (key-10.4103/2277-9175.270133-68) 2004
Yoshida (key-10.4103/2277-9175.270133-1) 2017
Pathiraja (key-10.4103/2277-9175.270133-67) 2010
Fritzsche (key-10.4103/2277-9175.270133-27) 2008
Yamaguchi (key-10.4103/2277-9175.270133-82) 2010
Kim (key-10.4103/2277-9175.270133-19) 2011
Zhang (key-10.4103/2277-9175.270133-25) 2013
Takai (key-10.4103/2277-9175.270133-56) 2010
Nakagawa (key-10.4103/2277-9175.270133-39) 2007
Marks (key-10.4103/2277-9175.270133-83) 2007
Takai (key-10.4103/2277-9175.270133-49) 2010
Chen (key-10.4103/2277-9175.270133-42) 2007
Liu (key-10.4103/2277-9175.270133-74) 2013
Siu (key-10.4103/2277-9175.270133-24) 2008
Parthun (key-10.4103/2277-9175.270133-22) 2007
Kitamura (key-10.4103/2277-9175.270133-85) 2012
Senese (key-10.4103/2277-9175.270133-16) 2007
Ceccacci (key-10.4103/2277-9175.270133-8) 2016
Krusche (key-10.4103/2277-9175.270133-61) 2005
Ouaïssi (key-10.4103/2277-9175.270133-89) 2011
Koutsounas (key-10.4103/2277-9175.270133-90) 2013
Chou (key-10.4103/2277-9175.270133-71) 2011
Marchion (key-10.4103/2277-9175.270133-55) 2007
Minucci (key-10.4103/2277-9175.270133-63) 2006
Zhang (key-10.4103/2277-9175.270133-62) 2004
Cacan (key-10.4103/2277-9175.270133-47) 2017
Moore (key-10.4103/2277-9175.270133-91) 2004
Hayashi (key-10.4103/2277-9175.270133-48) 2010
Wild (key-10.4103/2277-9175.270133-32) 2005
Dokmanovic (key-10.4103/2277-9175.270133-64) 2005
Ansari (key-10.4103/2277-9175.270133-96) 2016
Ouaïssi (key-10.4103/2277-9175.270133-86) 2008
Jones (key-10.4103/2277-9175.270133-3) 2011
Geng (key-10.4103/2277-9175.270133-97) 2006
Lagger (key-10.4103/2277-9175.270133-38) 2002
Yeo (key-10.4103/2277-9175.270133-77) 2012
Weberpals (key-10.4103/2277-9175.270133-50) 2011
Pruitt (key-10.4103/2277-9175.270133-66) 2006
Muscolini (key-10.4103/2277-9175.270133-51) 2008
Cress (key-10.4103/2277-9175.270133-15) 2000
Atmaca (key-10.4103/2277-9175.270133-60) 2007
Khabele (key-10.4103/2277-9175.270133-45) 2007
Jung (key-10.4103/2277-9175.270133-43) 2005
Yang (key-10.4103/2277-9175.270133-20) 2018
Bolden (key-10.4103/2277-9175.270133-5) 2006
Sami (key-10.4103/2277-9175.270133-37) 2008
Vanaja (key-10.4103/2277-9175.270133-57) 2018
Verdin (key-10.4103/2277-9175.270133-18) 2003
Huang (key-10.4103/2277-9175.270133-59) 2005
Kim (key-10.4103/2277-9175.270133-75) 2009
References_xml – start-page: 35
  year: 2010
  ident: key-10.4103/2277-9175.270133-67
  article-title: Epigenetic regulation in estrogen receptor positive breast cancer – Role in treatment response
  publication-title: J Mammary Gland Biol Neoplasia
  doi: 10.1007/s10911-010-9166-0
– start-page: 273
  year: 2004
  ident: key-10.4103/2277-9175.270133-40
  article-title: Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells
  publication-title: Eur J Histochem
– start-page: 1181
  year: 2010
  ident: key-10.4103/2277-9175.270133-33
  article-title: Inhibition of bladder tumour growth by histone deacetylase inhibitor
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2009.08795.x
– start-page: 1241
  year: 2004
  ident: key-10.4103/2277-9175.270133-34
  article-title: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0307708100
– start-page: 604
  year: 2008
  ident: key-10.4103/2277-9175.270133-41
  article-title: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604199
– start-page: e2856
  year: 2017
  ident: key-10.4103/2277-9175.270133-80
  article-title: Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2016.457
– start-page: e40
  year: 2006
  ident: key-10.4103/2277-9175.270133-66
  article-title: Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.0020040
– start-page: 583
  year: 2007
  ident: key-10.4103/2277-9175.270133-55
  article-title: Development of histone deacetylase inhibitors for cancer treatment
  publication-title: Expert Rev Anticancer Ther
  doi: 10.1586/14737140.7.4.583
– start-page: 297
  year: 2017
  ident: key-10.4103/2277-9175.270133-1
  article-title: Chemical and structural biology of protein lysine deacetylases
  publication-title: Proc Jpn Acad Ser B Phys Biol Sci
  doi: 10.2183/pjab.93.019
– start-page: 416
  year: 2004
  ident: key-10.4103/2277-9175.270133-99
  article-title: Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death
  publication-title: Surgery
  doi: 10.1016/j.surg.2004.05.018
– start-page: 75
  year: 2007
  ident: key-10.4103/2277-9175.270133-13
  article-title: Functions of site-specific histone acetylation and deacetylation
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev.biochem.76.052705.162114
– start-page: 12
  year: 2012
  ident: key-10.4103/2277-9175.270133-14
  article-title: Cancer epigenetics: From mechanism to therapy
  publication-title: Cell
  doi: 10.1016/j.cell.2012.06.013
– start-page: 5528
  year: 2007
  ident: key-10.4103/2277-9175.270133-21
  article-title: Chemistry of acetyl transfer by histone modifying enzymes: Structure, mechanism and implications for effector design
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210619
– start-page: 523
  year: 2008
  ident: key-10.4103/2277-9175.270133-88
  article-title: Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.7.4.5480
– start-page: 293
  year: 2005
  ident: key-10.4103/2277-9175.270133-64
  article-title: Prospects: Histone deacetylase inhibitors
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.20532
– start-page: 1
  year: 2000
  ident: key-10.4103/2277-9175.270133-15
  article-title: Histone deacetylases, transcriptional control, and cancer
  publication-title: J Cell Physiol
  doi: 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
– start-page: 60
  year: 2013
  ident: key-10.4103/2277-9175.270133-74
  article-title: Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2013.07.022
– start-page: 395
  year: 2005
  ident: key-10.4103/2277-9175.270133-59
  article-title: Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
  publication-title: Cell Death Differ
  doi: 10.1038/sj.cdd.4401567
– start-page: 409
  year: 2016
  ident: key-10.4103/2277-9175.270133-81
  article-title: Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2015.3240
– start-page: 655
  year: 2009
  ident: key-10.4103/2277-9175.270133-75
  article-title: Anti-invasive activity of histone deacetylase inhibitors via the induction of egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells
  publication-title: BMB Rep
  doi: 10.5483/BMBRep.2009.42.10.655
– start-page: 1
  year: 2010
  ident: key-10.4103/2277-9175.270133-49
  article-title: Histone deacetylase inhibitor therapy in epithelial ovarian cancer
  publication-title: J Oncol
  doi: 10.1155/2010/458431
– start-page: 286
  year: 2003
  ident: key-10.4103/2277-9175.270133-18
  article-title: Class II histone deacetylases: Versatile regulators
  publication-title: Trends Genet
  doi: 10.1016/S0168-9525(03)00073-8
– start-page: 2760
  year: 2004
  ident: key-10.4103/2277-9175.270133-52
  article-title: Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis
  publication-title: Cancer
  doi: 10.1002/cncr.20709
– start-page: 2376
  year: 2009
  ident: key-10.4103/2277-9175.270133-36
  article-title: The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinomain vitro and in vivo
  publication-title: J Cell Mol Med
  doi: 10.1111/j.1582-4934.2008.00436.x
– start-page: 4458
  year: 2007
  ident: key-10.4103/2277-9175.270133-79
  article-title: Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v13.i33.4458
– start-page: 5319
  year: 2007
  ident: key-10.4103/2277-9175.270133-22
  article-title: Hat1: The emerging cellular roles of a type B histone acetyltransferase
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210602
– start-page: e18087
  year: 2011
  ident: key-10.4103/2277-9175.270133-71
  article-title: HDAC inhibition decreases the expression of EGFR in colorectal cancer cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0018087
– start-page: 161
  year: 2014
  ident: key-10.4103/2277-9175.270133-6
  article-title: Histone deacetylase inhibitors in cancer therapy.A review
  publication-title: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  doi: 10.5507/bp.2013.085
– start-page: 3898
  year: 2015
  ident: key-10.4103/2277-9175.270133-26
  article-title: Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents
  publication-title: Molecules
  doi: 10.3390/molecules20033898
– start-page: 155
  year: 2016
  ident: key-10.4103/2277-9175.270133-96
  article-title: Epigenetics in non-small cell lung cancer: From basics to therapeutics
  publication-title: Transl Lung Cancer Res
  doi: 10.21037/tlcr.2016.02.02
– start-page: 3012
  year: 2011
  ident: key-10.4103/2277-9175.270133-3
  article-title: Protein acetylation in prokaryotes
  publication-title: Proteomics
  doi: 10.1002/pmic.201000812
– start-page: 1021
  year: 2008
  ident: key-10.4103/2277-9175.270133-46
  article-title: Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas
  publication-title: Neoplasia
  doi: 10.1593/neo.08474
– ident: key-10.4103/2277-9175.270133-12
  doi: 10.3390/nu10060731
– start-page: 1410
  year: 2008
  ident: key-10.4103/2277-9175.270133-51
  article-title: Trichostatin A up-regulates p73 and induces bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-08-0299
– start-page: 3361
  year: 2012
  ident: key-10.4103/2277-9175.270133-77
  article-title: Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: A multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the mayo phase II consortium and the cancer therapeutics research group
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.41.2395
– start-page: 455
  year: 2004
  ident: key-10.4103/2277-9175.270133-68
  article-title: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(04)00114-X
– start-page: e7663
  year: 2017
  ident: key-10.4103/2277-9175.270133-93
  article-title: Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000007663
– start-page: 3535
  year: 2005
  ident: key-10.4103/2277-9175.270133-29
  article-title: Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1092
– start-page: 64
  year: 2007
  ident: key-10.4103/2277-9175.270133-65
  article-title: Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.6.1.3549
– start-page: 10
  year: 2014
  ident: key-10.4103/2277-9175.270133-31
  article-title: Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer
  publication-title: BMC Clin Pathol
  doi: 10.1186/1472-6890-14-10
– start-page: 177
  year: 2007
  ident: key-10.4103/2277-9175.270133-60
  article-title: Valproic acid (VPA) in patients with refractory advanced cancer: A dose escalating phase I clinical trial
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6603851
– start-page: 38
  year: 2006
  ident: key-10.4103/2277-9175.270133-63
  article-title: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1779
– start-page: 795
  year: 2007
  ident: key-10.4103/2277-9175.270133-45
  article-title: Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.6.5.4007
– start-page: e64600
  year: 2013
  ident: key-10.4103/2277-9175.270133-70
  article-title: HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0064600
– start-page: 145
  year: 2005
  ident: key-10.4103/2277-9175.270133-95
  article-title: Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2005.02.006
– start-page: 769
  year: 2007
  ident: key-10.4103/2277-9175.270133-39
  article-title: Expression profile of class I histone deacetylases in human cancer tissues
  publication-title: Oncol Rep
– start-page: 300
  year: 2008
  ident: key-10.4103/2277-9175.270133-44
  article-title: The role of histone deacetylases in prostate cancer
  publication-title: Epigenetics
  doi: 10.4161/epi.3.6.7273
– start-page: 15
  year: 2005
  ident: key-10.4103/2277-9175.270133-61
  article-title: Histone deacetylase-1 and -3 protein expression in human breast cancer: A tissue microarray analysis
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-004-1668-2
– start-page: 357
  year: 2008
  ident: key-10.4103/2277-9175.270133-37
  article-title: Valproic acid inhibits the growth of cervical cancer bothin vitro and in vivo
  publication-title: J Biochem
  doi: 10.1093/jb/mvn074
– start-page: 21
  year: 2004
  ident: key-10.4103/2277-9175.270133-35
  article-title: P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207020
– start-page: 11298
  year: 2006
  ident: key-10.4103/2277-9175.270133-97
  article-title: Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-0049
– start-page: 1332
  year: 2010
  ident: key-10.4103/2277-9175.270133-48
  article-title: Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin
  publication-title: Int J Cancer
  doi: 10.1002/ijc.25151
– start-page: 109
  year: 2018
  ident: key-10.4103/2277-9175.270133-20
  article-title: Epigenetics in ovarian cancer: Premise, properties, and perspectives
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0855-4
– start-page: 2672
  year: 2002
  ident: key-10.4103/2277-9175.270133-38
  article-title: Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
  publication-title: EMBO J
  doi: 10.1093/emboj/21.11.2672
– start-page: e80657
  year: 2013
  ident: key-10.4103/2277-9175.270133-58
  article-title: Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0080657
– start-page: 261
  year: 2013
  ident: key-10.4103/2277-9175.270133-92
  article-title: Targeting the epigenome in lung cancer: Expanding approaches to epigenetic therapy
  publication-title: Front Oncol
– start-page: 605
  year: 2016
  ident: key-10.4103/2277-9175.270133-8
  article-title: Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2016.36
– start-page: 381
  year: 2008
  ident: key-10.4103/2277-9175.270133-27
  article-title: Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-8-381
– start-page: 29
  year: 2011
  ident: key-10.4103/2277-9175.270133-50
  article-title: The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
  publication-title: Cancer Cell Int
  doi: 10.1186/1475-2867-11-29
– start-page: 6962
  year: 2004
  ident: key-10.4103/2277-9175.270133-62
  article-title: HDAC6 expression is correlated with better survival in breast cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0455
– start-page: 84
  year: 2012
  ident: key-10.4103/2277-9175.270133-85
  article-title: The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2012.01.018
– start-page: 1452
  year: 2005
  ident: key-10.4103/2277-9175.270133-43
  article-title: Rational design and development of radiation-sensitizing histone deacetylase inhibitors
  publication-title: Chem Biodivers
  doi: 10.1002/cbdv.200590118
– start-page: 5318
  year: 2007
  ident: key-10.4103/2277-9175.270133-42
  article-title: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting ku70 acetylation
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-3996
– start-page: 1
  year: 2010
  ident: key-10.4103/2277-9175.270133-56
  article-title: Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer
  publication-title: Obstet Gynecol Int
  doi: 10.1155/2010/923824
– start-page: 167
  year: 2004
  ident: key-10.4103/2277-9175.270133-91
  article-title: Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbamcr.2004.07.001
– start-page: 1397
  year: 2004
  ident: key-10.4103/2277-9175.270133-98
  article-title: The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.1397.3.11
– start-page: 1940
  year: 2008
  ident: key-10.4103/2277-9175.270133-24
  article-title: Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.5730
– start-page: 84
  year: 2007
  ident: key-10.4103/2277-9175.270133-83
  article-title: Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1272
– start-page: 381
  year: 2011
  ident: key-10.4103/2277-9175.270133-23
  article-title: Regulation of chromatin by histone modifications
  publication-title: Cell Res
  doi: 10.1038/cr.2011.22
– start-page: 2318
  year: 2008
  ident: key-10.4103/2277-9175.270133-86
  article-title: High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-008-9940-z
– start-page: 1
  year: 2016
  ident: key-10.4103/2277-9175.270133-7
  article-title: HDAC inhibitors as epigenetic regulators of the immune system: Impacts on cancer therapy and inflammatory diseases
  publication-title: Biomed Res Int
  doi: 10.1155/2016/8797206
– start-page: 733
  year: 2013
  ident: key-10.4103/2277-9175.270133-25
  article-title: Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors
  publication-title: Onco Targets Ther
– start-page: 1
  year: 2011
  ident: key-10.4103/2277-9175.270133-89
  article-title: Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer
  publication-title: J Biomed Biotechnol
  doi: 10.1155/2011/315939
– start-page: 355
  year: 2010
  ident: key-10.4103/2277-9175.270133-82
  article-title: Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2009.01387.x
– ident: key-10.4103/2277-9175.270133-94
– start-page: 2548
  year: 2007
  ident: key-10.4103/2277-9175.270133-53
  article-title: Human endometrial and ovarian cancer cells: Histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis
  publication-title: Curr Med Chem
  doi: 10.2174/092986707782023299
– start-page: 633
  year: 2007
  ident: key-10.4103/2277-9175.270133-4
  article-title: New nomenclature for chromatin-modifying enzymes
  publication-title: Cell
  doi: 10.1016/j.cell.2007.10.039
– start-page: 1057
  year: 2010
  ident: key-10.4103/2277-9175.270133-76
  article-title: Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma
  publication-title: Autophagy
  doi: 10.4161/auto.6.8.13365
– start-page: 1
  year: 2015
  ident: key-10.4103/2277-9175.270133-54
  article-title: Potential therapeutic targets in uterine sarcomas
  publication-title: Sarcoma
  doi: 10.1155/2015/243298
– start-page: 67
  year: 2009
  ident: key-10.4103/2277-9175.270133-72
  article-title: DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
  publication-title: BMC Med Genomics
  doi: 10.1186/1755-8794-2-67
– start-page: 163
  issn: 2277-9175
  year: 2017
  ident: key-10.4103/2277-9175.270133-11
  article-title: Effect of genistein and 17-β estradiol on the viability and apoptosis of human hepatocellular carcinoma hepG2 cell line
  publication-title: Adv Biomed Res
– start-page: e2020
  year: 2008
  ident: key-10.4103/2277-9175.270133-17
  article-title: The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0002020
– start-page: 166
  year: 2011
  ident: key-10.4103/2277-9175.270133-19
  article-title: Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs
  publication-title: Am J Transl Res
– start-page: 173
  year: 2017
  ident: key-10.4103/2277-9175.270133-47
  article-title: Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells
  publication-title: J Chemother
  doi: 10.1080/1120009X.2016.1277007
– start-page: 129
  year: 2011
  ident: key-10.4103/2277-9175.270133-73
  article-title: Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC
  publication-title: Virchows Arch
  doi: 10.1007/s00428-011-1103-0
– start-page: 1245
  year: 2006
  ident: key-10.4103/2277-9175.270133-87
  article-title: Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2006.07.185
– start-page: 4538
  year: 2007
  ident: key-10.4103/2277-9175.270133-28
  article-title: Synergisticin vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-0014
– start-page: 813
  year: 2013
  ident: key-10.4103/2277-9175.270133-90
  article-title: Current evidence for histone deacetylase inhibitors in pancreatic cancer
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v19.i6.813
– start-page: 12
  year: 2018
  ident: key-10.4103/2277-9175.270133-9
  article-title: Comparative analysis of the effects of valproic acid and tamoxifen on proliferation, and apoptosis of human hepatocellular carcinoma WCH 17 celllin
  publication-title: Iran J Peadiatr Hematol Oncol
– start-page: 769
  year: 2006
  ident: key-10.4103/2277-9175.270133-5
  article-title: Anticancer activities of histone deacetylase inhibitors
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd2133
– ident: key-10.4103/2277-9175.270133-10
– start-page: e0136193
  year: 2015
  ident: key-10.4103/2277-9175.270133-84
  article-title: Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT/mTOR signaling
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0136193
– start-page: 20
  year: 2018
  ident: key-10.4103/2277-9175.270133-57
  article-title: Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6
  publication-title: Cell Commun Signal
  doi: 10.1186/s12964-018-0231-4
– start-page: 162
  year: 2001
  ident: key-10.4103/2277-9175.270133-2
  article-title: Functional significance of histone deacetylase diversity
  publication-title: Curr Opin Genet Dev
  doi: 10.1016/S0959-437X(00)00174-X
– start-page: 840
  year: 2009
  ident: key-10.4103/2277-9175.270133-30
  article-title: Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1918
– start-page: 4784
  year: 2007
  ident: key-10.4103/2277-9175.270133-16
  article-title: Role for histone deacetylase 1 in human tumor cell proliferation
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.00494-07
– start-page: 363
  year: 2007
  ident: key-10.4103/2277-9175.270133-69
  article-title: Dietary histone deacetylase inhibitors: From cells to mice to man
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2007.04.001
– start-page: 632
  year: 2017
  ident: key-10.4103/2277-9175.270133-78
  article-title: Emerging molecular therapeutic targets for cholangiocarcinoma
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.03.026
– start-page: 4415
  year: 2005
  ident: key-10.4103/2277-9175.270133-32
  article-title: Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-0259
SSID ssj0000684659
Score 2.4099095
SecondaryResourceType review_article
Snippet Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs)...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
wolterskluwer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 63
SubjectTerms Acetylation
Angiogenesis
Apoptosis
Biochemistry
Cancer
Cancer cells
Carcinogenesis
Carcinogens
Cell cycle
Cell death
Cell differentiation
Classification
Deacetylation
Deoxyribonucleic acid
Development and progression
Differentiation (biology)
DNA
DNA methylation
Enzymes
Epigenetic inheritance
Epigenetics
Fatty acids
Gene expression
Genes
Histone deacetylase
histone deacetylase inhibitors
Histones
Immune system
Inhibitors
Lung cancer
Molecular modelling
Peptides
Proteins
Review
Romidepsin
Therapeutic applications
Tumorigenesis
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQDwgJIb4JFGQQEqfQJHYchxNLoWqRlgNQ1JsVf9FAm0XrXSH-PTNOdkmAiguHvaxnV_bMi-dNbD8T8jRjlpc156l1NU-5rXQqATppYaQ2UB9YHdX25-_E4TF_e1KejK76wj1hvTxw77g9CwnNQpITRktce9SF9VxC3iyFb8omUqOszkbFVD8HQ16NN6UVcY0SkmSv2MjzjO01evkcPkB7C4USO6OMFIX7_5yeR_np972TV78vcF07fI3b2kfJ6eA6uTawSjrrR3ODXHLdTXJ5Pqyb3yJfohpI5-hrmAHd6gdQZhdo01n6lwZ61J22usVreF7Q-eb6XDp3eEi4DeeBLjydxfMQtO3oJ6i2F-tA9xE_y3CbHB-8-bh_mA63LKSmysuzlDHmmcisll7i-fKCscpo46vcCem9gQKJOS9tzaEWkb7WRgpfijpvXG1trtkdstNBR-8RCnGxFdRvQnjDPUylVV5k0gDDbKTnNk9IuvG0MoMEOd6EcaagFMHIKIzKr8gk5NnW_lsvvnGh5SsM3NYKRbPjFwAlNUBJ_QtKCXmCYVcoi9HhvpvPzToEdfThvZqJHJge0OUS-jQY-QX03TTDMQbwACppTSx3J5bw3Jpp8wZdapg3ggK2DXgFFgYjerxtxl_iXrjOQTjRpiwLCTwsIXd7MG7HDaNjUAFmCakmMJ04ZtrStadRVVwgVa7gP19OAK3O-2OZFzheCaYGpKoNUu__j2A8IFfATXX_tmuX7KyWa_cQ-N9KP4qP-k_eG1iG
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdGJyEkhPgmMJBBSDyFJbHjOEgIurFpQ-qEBkN7s-KvrbAlo2mF-O-5y0fXAOOhL_W1ss_n8-9s3-8IeRkxy9Oc89C6nIfcZjqUYDphYqQ2EB9Y3bDtTw7E3hH_eJwer5GDPhcGn1X2PrFx1LYyeEa-CTgkyTLYn_J3Fz9CrBqFt6t9CY2iK61g3zYUY9fIOrjkNBqR9a2dg0-Hy1OXSMB-m-YteyOPI7ZZ6Nlr-AAEThTS7azsTg2J_9-uemWv-vMd5c2fFd5x19-bJ-4rG9XubXKrQ5h03JrEHbLmyrvk-qS7Q79HvjXMIKWjH8AbuvkvgM-upkVp6T8a6H55OtVTLMnzhk76Urp04jBheFqf17TydNzkRtBpSb9C5F0tarqNtjSr75Oj3Z0v23thV3EhNKDas5Ax5pmIrJZeYq55wlhmtPFZ7IT03kCwxJyXNucQl0ifayOFT0UeFy63NtbsARmV0NFHhHIpbAaxnBDecA9uNYuTSBpAm4X03MYBCXtNK9PRkWNVjDMFYQnOjMJZuZyZgLxayl-0RBxXSm7hxC2lkEC7-aKanahuPSoLOMkCdhJGS7zS1on10GUInoQv0qIIyAucdoUUGSW-wTkpFnWt9j8fqrGIAfUBdE6hT52Qr6DvpuhSGkADyKo1kNwYSMIaNsPm3rpU50NqdWnxAXm-bMZf4ru40sF0okyaJhIwWUAetsa4HDeMjkE0GAUkG5jpQDHDlnJ62jCMC4TNGfzn-4FBq_M2RfMKxSvBVGepqrfUx_8f2RNyAxSQt2daG2Q0ny3cU0B5c_2sW7q_ASZMVN8
  priority: 102
  providerName: ProQuest
– databaseName: Medknow Open Access Journals
  dbid: W3E
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLamISEkhLgvMJBBSDwFkjhxHCIkymDakMoDY7A3y9ctsCWoaUH79xw7btcAe-KhUlWfJva52N_x5TNCzxKi86LK81ibKo9zXcqYgevEmWJSQX6gpWfbn36ke4f5h6PiaAMt1nZVCv1TNh0kmz45Dwr0x7p8WGR-0RFGvfocfMHN8VV1iGRWh8rWQzRSUpvlF7EANDp_fSBaYZraMxJBpn8lK9PKBcNXcjE1k1AYlP01a6t3DXSPeZqQl0LOXsAHMHPGHT_P2nDmWf__7tvXBrc_N15e_9W5RfH-u98Tvzay7d5ENwIkxZNBBbfQhmlvo6vTsOh-B33zVCKtwe-g-zTzc2ih6bFoNf5HAd5vTxrZuDt8XuHp8u5dPDXuhHHTn_W4s3jiD1PgpsVfIFXvFj3ecc436--iw933n3f24nBFQ6zKtDiNCSGW0ERLZpk7nJ4RUiqpbJkayqxVkF0RY5muckhkmK2kYtQWtEqFqbROJbmHNluo6BbCOaO6hOSPUqtyC_1wmWYJUwBPBbO5TiMULzXNVeAvd9donHLIY5xluLPKhWUi9Hwl_2Ng7rhU8q0z3ErKMW77H7rZMQ_-xzUAKw1giyrJ3Bq4zLSFKkO2Ra0ohIjQU2d27jg1Wrdp51gs-p7vH3ziE5oCTASsXUCdgpDtoO5KhDMQoAFHwzWS3B5JQtCrcfHSu3jodHoOUB38FSActOjJqtj9022kaw2Y08kURcYAxEXo_uCMq3ZD6wikj0mEypGbjhQzLmmbE09JTh3OLuGZb0YOzc-GM52XKJ5TwoOn8qWnPvj_RzxE11yvMEyUbaPN-WxhHgF0nMvHPtB_AyXFcG0
  priority: 102
  providerName: Wolters Kluwer Health
Title Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
URI http://www.advbiores.net/article.asp?issn=2277-9175;year=2019;volume=8;issue=1;spage=63;epage=63;aulast=Sanaei;type=0
https://www.ncbi.nlm.nih.gov/pubmed/31737580
https://www.proquest.com/docview/2312771519
https://www.proquest.com/docview/2315528613
https://pubmed.ncbi.nlm.nih.gov/PMC6839273
https://doaj.org/article/d091d3176cb84466b2df4865856fa5aa
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELZgkxASQvwchVEZhMRTShM7jsMLdKNlQ-qEBoW-WbEdb4UuhaYV7L_nzkm7BTqJh6ZSfY2cu7P9XXz-jpAXXWZ5nHIe2DzlAbeJDiS4ThAZqQ3EB1Z7tv3hkTgY8Q_jeHyR_1QrsNwY2mE9qdF82vn98_wNDHjArx0edtmrTM878AEUGylkAN32e0WYxldD_WpWhpXW106L_K4lLJsVh-OGWzTWKE_l_--EfWnF-jub8tavGe50l999ovul5Wpwh9yucSbtVY5xl1zLi3vkxrDeSb9Pvnl-kCKn72BOzBfnAKLzkmaFpRsa6GFxOtETLMzzmg5XBXXpMMdjw5PyrKQzR3v-hASdFPQLxN-zZUn30aPm5QMyGvQ_7x8Edd2FwCRhPA0YY46JrtXSSTxxHjGWGG1cEuZCOmcgZGK5kzblEJ1Il2ojhYtFGmZ5am2o2UOyVUBHHxHKpbAJRHRCOMMdTK5JGHWlAcyZScdt2CLBStPK1KTkWBtjqiA4QcsotMqFZVrk5Vr-R0XHcaXkHhpuLYU02v6H2fxE1aNSWUBLFhCUMFrixraOrIMuQwglXBZnWYs8R7MrJMooMBPnJFuWpTr8dKx6IgTsBwA6hj7VQm4GfTdZfbABNIDcWg3J3YYkjGTTbF55l1oNBAX4G_wVcBk80bN1M_4Ts-OKHMyJMnEcSUBmLbJTOeP6ueHpGMSE3RZJGm7aUEyzpZicep5xgeA5gXu-bTi0OqsOal6heCWYqj1VrTz18X-r6Am5Cd9p9ZJrl2wt5sv8KcC-hW6T68k4gascvG-T7b3-0cfjtn-F0vYjHa5fWf8PD0xdRw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkAAJIb4JDDAIxFNYEieOg4SgbEwrW_cAG-qbib-2wpaOptW0f4q_kbt8dA0w3vbQl_oSOXfnu9_ZvjtCXgTMxEkWx76xWezHJlW-ANXxIy2UhvjAqKra_mCHb-7Fn4bJcIn8anNh8FplaxMrQ23GGvfIVwGHRGkK_il7d_zTx65ReLrattCo1WLLnp5AyFa-7a-DfF9G0cbH3bVNv-kq4Gt4_NBnjDnGA6OEE5hPHTGWaqVdGlounNMQEDDrhMliwN7CZUoL7hKehbnNjAkVg_deIpdjPGKE9ZMO0_meTsDBmydZXRsyDgO2mqvJa_gBwI4kFvNZ8H1Vi4C_HcGCJ_zzlub1kzGeoJc_qgv0C25w4ya50eBX2qsV7hZZssVtcmXQnNDfId-ruiOFpetga-30FMC5LWleGPqPAdovDkZqhA1_3tBB26iXDiymI4_Ko5KOHe1VmRd0VNCvENePZyVdQ02dlHfJ3oVw_h5ZLmCiDwiNBTcpRIqcOx07MNppGAVCA5bNhYtN6BG_5bTUTbFz7LlxKCHoQclIlMqZZDzyak5_XJf5OJfyAwpuToXluas_xpN92ax2aQCFGUBmXCuBB-YqMg6mDKEZd3mS5x55jmKXWICjwBs--_msLGX_y2fZ4yFgSgDmCcypIXJjmLvOm4QJ4ADW7OpQrnQowULo7nCrXbKxUKU8W08eeTYfxifx1l1hQZxIkySRAMTnkfu1Ms6_G76OQawZeCTtqGmHMd2RYnRQ1S_nCMpTeOf7jkLLozoB9BzGS85ko6my1dSH__-yp-Tq5u5gW273d7YekWvAjKzePVshy9PJzD4GPDlVT6pFTMm3i7YavwF5oYs1
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Histone+Deacetylases+and+Histone+Deacetylase+Inhibitors%3A+Molecular+Mechanisms+of+Action+in+Various+Cancers&rft.jtitle=Advanced+biomedical+research&rft.au=Sanaei%2C+Masumeh&rft.au=Kavoosi%2C+Fraidoon&rft.date=2019-01-01&rft.pub=Medknow+Publications+and+Media+Pvt.+Ltd&rft.issn=2277-9175&rft.eissn=2277-9175&rft.volume=8&rft.issue=1&rft.spage=63&rft_id=info:doi/10.4103%2Fabr.abr_142_19&rft.externalDocID=A611720135
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2277-9175&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2277-9175&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2277-9175&client=summon